Daniel Stauder
Stock Analyst at Citizens
(2.70)
# 1,104
Out of 5,152 analysts
23
Total ratings
42.86%
Success rate
9.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LMAT LeMaitre Vascular | Maintains: Market Outperform | $113 → $118 | $106.15 | +11.16% | 5 | Feb 26, 2026 | |
| ATRC AtriCure | Maintains: Market Outperform | $60 → $52 | $30.31 | +71.56% | 7 | Feb 18, 2026 | |
| STXS Stereotaxis | Initiates: Market Outperform | $4 | $2.19 | +82.65% | 1 | Dec 16, 2025 | |
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $37.86 | +39.99% | 7 | Nov 7, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.41 | +396.45% | 1 | Mar 5, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $570.49 | +27.08% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $13.79 | - | 1 | May 7, 2024 |
LeMaitre Vascular
Feb 26, 2026
Maintains: Market Outperform
Price Target: $113 → $118
Current: $106.15
Upside: +11.16%
AtriCure
Feb 18, 2026
Maintains: Market Outperform
Price Target: $60 → $52
Current: $30.31
Upside: +71.56%
Stereotaxis
Dec 16, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.19
Upside: +82.65%
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $37.86
Upside: +39.99%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.41
Upside: +396.45%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $570.49
Upside: +27.08%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $13.79
Upside: -